Stock listing

NASDAQ:VTVT vTv Therapeutics Inc. Stock

Home listing (NASDAQ) of vTv Therapeutics Inc.

Follow vTv Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VTVT

$15.51 USD -0.72 (-4.4%)

Close on Nov 20, 2026

Past year -50.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$15.47 – $16.47 USDNov 20, 2026
Volume
10,588 sharesNov 20, 2026
Market cap
$61.33M USDAt the close on Nov 20, 2026 · price × 3.95M shares outstanding
52-week range
$15.47 – $44.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$990,961 USDMedian day 22,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
vTv Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VTVT · Home$15.51 USD-0.72 (-4.4%)10,588$15.96$16.47$15.47$16.23Close on Nov 20, 2026
Frankfurt:5VT0€14.50 EUR-0.10 (-0.7%)—€14.50€14.50€14.50€14.60Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VTVT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$15.51-0.72-4.4%$15.96$16.47$15.4710,588
$16.23-1.06-6.1%$16.19$16.77$16.0021,716
$17.29-0.40-2.3%$16.89$18.00$16.7126,819
$17.69-2.00-10.2%$19.41$19.41$17.2820,851
$19.69-1.00-4.8%$20.81$20.81$19.3217,403
$20.69-0.78-3.6%$21.30$21.30$20.5570,982
$21.47+0.47+2.2%$21.24$21.72$21.0411,733
$21.00-0.18-0.8%$21.42$22.64$20.8624,683
$21.18+0.15+0.7%$21.06$21.47$20.7613,219
$21.03-0.71-3.3%$21.85$22.20$20.5614,365
$21.74-2.29-9.5%$23.10$23.10$21.7217,774
$24.03+0.48+2.0%$23.55$24.38$23.5528,577
$23.55-0.60-2.5%$22.85$25.26$22.8537,929
$24.15-1.02-4.1%$24.72$24.72$23.7220,787
$25.17-1.21-4.6%$25.85$26.31$24.6914,217
$26.38+0.66+2.6%$26.17$27.00$25.7641,638
$25.720.000.0%$25.55$25.96$25.0017,881
$25.72-0.09-0.3%$26.06$26.44$25.4711,112
$25.81+0.26+1.0%$25.74$26.56$25.7014,607
$25.55-1.61-5.9%$27.31$27.31$25.3521,500
$27.16-0.61-2.2%$27.79$28.05$27.0210,800
$27.77-0.075-0.3%$28.06$29.24$27.5514,100
$27.85+0.905+3.4%$27.47$28.56$27.0721,200
$26.94+0.40+1.5%$26.70$27.23$26.6117,900
$26.54-1.05-3.8%$27.49$27.49$25.9511,800
$27.59+0.07+0.3%$27.80$28.87$27.4222,200
$27.52-0.71-2.5%$27.91$28.86$27.4920,100
$28.23-2.23-7.3%$30.75$31.22$27.8741,800
$30.46-0.72-2.3%$31.12$31.18$30.2917,100
$31.18+1.10+3.7%$30.16$31.18$30.1012,800
$30.08-0.93-3.0%$31.03$31.22$29.8044,300
$31.01+0.98+3.3%$29.95$31.50$29.8626,100
$30.03-0.30-1.0%$30.50$30.50$29.5527,900
$30.33-0.24-0.8%$31.56$31.56$30.2914,900
$30.57-1.28-4.0%$32.20$32.32$30.5718,000
$31.85+1.01+3.3%$30.99$32.28$30.9934,300
$30.84+0.84+2.8%$30.11$31.14$29.9830,900
$30.00-0.52-1.7%$30.34$30.69$30.0085,100
$30.52+0.31+1.0%$29.75$31.45$29.68111,900
$30.21-0.52-1.7%$30.60$30.91$29.7928,800
$30.73+0.15+0.5%$30.57$31.57$30.2418,000
$30.58-0.52-1.7%$31.03$31.40$30.4718,900
$31.10-0.20-0.6%$31.32$32.38$31.0711,200
$31.30-0.50-1.6%$31.45$32.00$31.0222,700
$31.80+0.40+1.3%$31.15$32.09$31.0574,400
$31.40+0.94+3.1%$30.89$32.11$30.7733,400
$30.460.000.0%$30.37$30.86$29.9891,500
$30.46-0.98-3.1%$31.30$31.90$29.7645,300
$31.44-0.53-1.7%$31.80$32.53$31.4422,200
$31.97+0.11+0.3%$32.24$32.54$31.2913,700
$31.86-1.43-4.3%$33.00$33.00$31.8546,300
$33.29+0.50+1.5%$32.99$34.14$32.7839,500
$32.79-0.56-1.7%$33.35$33.38$32.4828,100
$33.35-0.12-0.4%$32.97$33.73$32.9712,100
$33.47+0.07+0.2%$33.96$33.96$32.8820,900
$33.40+1.45+4.5%$32.55$34.00$32.1539,800
$31.95-0.05-0.2%$31.81$32.59$31.5552,700
$32.00-0.36-1.1%$32.25$32.25$31.3594,200
$32.36-0.44-1.3%$32.79$33.00$31.8090,200
$32.80-0.77-2.3%$33.07$34.09$32.5758,400
$33.57-0.34-1.0%$33.55$34.76$32.90117,200
$33.91+0.02+0.1%$33.80$34.55$33.4559,300
$33.89+0.635+1.9%$33.42$34.66$32.8718,000
$33.26+0.175+0.5%$33.19$33.85$32.7826,700
$33.08+0.185+0.6%$32.54$33.54$31.8462,700

Splits

1 split · NASDAQ:VTVT · every price before a split is adjusted for it

DayRatioWhat
1-for-40Consolidation
Ticker
NASDAQ:VTVT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All vTv Therapeutics Inc. news

vTv Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 103 in all · newest Nov 5, 2026 · oldest 2019
Decks
18 decks · latest Mar 10, 2026

Where vTv Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VTVT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:VTVTBOATSUnited StatesUSD
Frankfurt:5VT0FrankfurtGermanyEUR
Lang & Schwarz:A3EWXGLang & SchwarzGermanyEUR
Stuttgart:5VT0StuttgartGermanyEUR
Tradegate:5VT0TradegateGermanyEUR

Valuation

EV/sales −0.4× against a median of 12.0×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$15.84M USD
P/E
Loss
EV/sales
−0.4×
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
Not reported
Operating margin
−29.8%
Net margin
−20.8%
Debt to equity
0.0×
Beta vs S&P 500
1.28

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
vTv Therapeutics Inc. · NASDAQ:VTVTUS$61.33M−US$15.84Mn/a−0.4×n/a0.9×−20.8%0.0×1.28
Lytix Biopharma ASA · OSL:LYTIXUS$63.10MUS$53.73Mn/an/an/a7.1×n/a0.0×n/a
Neumora Therapeutics, Inc. · NASDAQ:NMRAUS$63.01MUS$30.65Mn/a1,916×n/a3.4×n/a2.9×1.07
Poolbeg Pharma PLC · LSE:POLBUS$61.42MUS$55.12Mn/an/an/a7.0×n/a0.0×n/a
Oncopeptides AB · OMXSTO:ONCOUS$61.25MUS$59.05Mn/a6.3×n/a25.1×−223.6%5.4×n/a
ViGenCell, Inc. · KRX:308080US$61.07MUS$44.61Mn/a65.1×n/a2.1×n/a0.2×n/a
HemoGenyx Pharmaceuticals PLC · LSE:HEMOUS$60.45MUS$56.88Mn/an/an/a10.7×n/a0.4×n/a
Genexine, Inc. · KRX:095700US$60.01MUS$44.21Mn/a12.0×n/a0.4×−650.0%0.0×n/a
GlycoNex, Inc. · TPEX:4168US$59.91MUS$57.19Mn/a84.9×n/a2.3×n/a0.6×n/a
ISU Abxis Co., Ltd. · KRX:086890US$59.84MUS$42.28Mn/a1.1×n/a0.7×−16.0%0.0×n/a
Rani Therapeutics Holdings, Inc. · NASDAQ:RANIUS$58.99MUS$16.85Mn/a2.6×n/a1.7×−493.0%0.1×2.21
Median of the othersUS$60.76MUS$49.17M12.0×2.9×−358.3%0.1×1.64

Forecasts

6 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
56.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.04 · 4 analysts
Revenue, year to Dec 2026
30.73M · 6 analysts

Team and board

Officers

OfficerRole
Paul SekhriChairman of the Board, President and Chief Executive Officer
Rich NelsonExecutive Vice President, Corporate Development

Board

DirectorRole
Paul SekhriChairman of the Board, President and Chief Executive Officer
Anne PhillipsDirector
Daniel K. SpiegelmanDirector
Fahed Al MarzooqiDirector
Raymond CheongLead Independent Director
Srinivas AkkarajuDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−3.3%
Q2 2026Aug 6, 2026 · After close+2.2%
Q1 2026May 13, 2026 · After close+21.4%
Q3 2025Nov 6, 2025 · After close+2.2%
Q2 2025Aug 14, 2025 · After close+0.9%
Q1 2025May 15, 2025 · After close−6.2%
Q4 2024Mar 11, 2025 · Before open−2.9%
Q3 2024Nov 12, 2024 · After close+7.1%
Q2 2024Aug 8, 2024 · After close−1.8%
Q1 2024May 9, 2024 · After close−3.1%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 13, 2024 · Before open+0.4%
Q3 2023Nov 9, 2023 · After close−6.8%
Q2 2023Aug 11, 2023 · After close+2.6%
Q1 2023May 11, 2023 · After close−5.5%
Q4 2022Mar 6, 2023 · After close−4.8%
Q3 2022Nov 10, 2022 · After close−2.4%
Q2 2022Aug 15, 2022 · After close−11.7%
Q1 2022May 12, 2022 · Before open−4.7%
Q4 2021Mar 29, 2022 · After close+0.3%
Quarter to Sep 30, 2021Nov 9, 2021 · Before open0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck25 slidesMar 10, 2026
Investor Presentation (February 2026)Investor deck25 slidesFeb 26, 2026
Investor Presentation (May 2025)Investor deck19 slidesMay 16, 2025
Investor Presentation (March 2025)Investor deck30 slidesMar 31, 2025
Investor Presentation (January 2025)Investor deck30 slidesJan 13, 2025
Investor Presentation (March 2024)Investor deck16 slidesMar 5, 2024
Investor Presentation (November 2023)Investor deck17 slidesNov 15, 2023
Investor Presentation (January 2023)Investor deck25 slidesJan 6, 2023
Investor Presentation (August 2020)Investor deck26 slidesAugust 2020
EASD 2020Conference17 slides2020
All 18 decks
DeckKindSlidesDate
EASD 2020Conference15 slides2020
Technical Presentation (March 2019)Technical16 slidesMar 30, 2019
Investor Presentation (February 2019)Investor deck29 slidesFeb 19, 2019
Technical Presentation (October 2018)Technical16 slidesOct 26, 2018
EASD 2017Conference15 slides2017
Keystone Symposia 2016Conference10 slidesApril 2016
Investor Presentation (November 2015)Investor deck29 slidesNov 17, 2015
Technical Presentation (July 2015)Technical13 slidesJul 17, 2015

Open Decks

Financings

RaiseDate
Private placement of units of Class A common stock or pre-funded warrants with accompanying warrants
Announced: US$80M · US$15.265 a unit · Warrants at US$22.71 · TD Cowen +1
Dealers: TD Cowen (co-lead), Evercore ISI (co-lead)
Buyers: Samsara BioCapital, L.P. (existing investor); T1D Fund (existing investor); Trails Edge Capital Partners (new investor); Invus (new investor)
Use of proceeds: Fund the ongoing CATT1 Phase 3 trial and continued development of cadisegliatin for type 1 diabetes
Sep 2, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Jul 29, 2015.

Price
US$15.00 a share
Shares offered
7,812,500 shares of Class A common stock
Offering size
US$117.2 million
Underwriters
Piper Jaffray, Stifel, Canaccord Genuity, Janney Montgomery Scott · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2015
Filed publiclyJun 15, 2015
Amended 6 timesNewest Jul 24, 2015
Declared effective by the SECJul 29, 2015
Shares registered with an exchangeJul 30, 2015
Final prospectus, with the priceJul 31, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Jul 31, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue01.02M02.02M4.00M6.41M2.76M12.4M291.0K634.0K
Cost of revenue16.0K89.0K90.0K92.0K89.0K11.0M15.1M23.0M39.6M45.7M
Gross profit-16.0K1.02M-90.0K2.02M4.00M-4.60M-12.4M-10.6M-39.3M-45.1M
Research and development17.9M11.5M13.6M12.4M13.3M11.0M15.1M23.0M39.6M45.0M
Selling, general and administrative14.9M13.7M11.9M12.2M12.3M7.25M8.54M9.22M11.3M9.91M
Operating income-32.8M-24.2M-25.5M-22.5M-21.7M-11.9M-20.9M-19.8M-50.7M-55.0M
Depreciation and amortization16.0K89.0K90.0K92.0K89.0K94.0K39.0K218.0K197.0K265.0K
EBITDA-32.8M-24.1M-25.4M-22.4M-21.6M-11.8M-20.9M-19.6M-50.5M-54.8M
Interest expense6.00K013.0K15.0K12.0K692.0K1.83M3.29M3.09M398.0K
Income before tax-31.1M-22.6M-26.0M-24.9M-17.6M-12.8M-21.8M-23.6M-53.8M-55.4M
Income tax0100.0K0200.0K115.0K0100.0K200.0K800.0K0
Net income-27.0M-18.5M-20.3M-19.2M-13.0M-8.50M-13.0M-7.91M-16.1M-16.4M
Earnings per share, basic-3.20-3.20-9.71-9.98-8.29-7.21-17.22-25.42-66.62-1.71

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents88.9M36.7M9.45M12.1M13.4M5.75M1.78M1.68M11.8M51.5M
Short-term investments85.0K65.0K15.0K100.0K371.0K250.0K1.12M162.0K0
Receivables62.0K102.0K173.0K57.0K158.0K5.00K08.00M0
Inventory15.0K100.0K371.0K250.0K162.0K0
Current assets89.9M38.1M10.7M27.1M15.6M7.21M2.84M3.47M20.4M52.1M
Property, plant and equipment28.0K117.0K207.0K278.0K367.0K461.0K70.0K283.0K444.0K
Goodwill00
Total assets89.9M38.3M11.0M33.2M25.5M14.8M9.27M8.56M27.9M54.5M
Accounts payable1.13M939.0K4.08M2.46M1.88M1.93M2.23M2.90M2.27M3.06M
Current liabilities6.64M5.20M10.6M7.71M8.50M6.39M13.4M18.8M26.9M11.4M
Long-term debt6.33M15.3M11.1M
Total debt169.0K529.0K716.0K932.0K915.0K5.18M15.3M19.6M11.1M
Total liabilities25.5M24.0M29.6M27.4M10.3M11.0M18.1M28.9M47.5M22.9M
Shareholders' equity64.4M12.2M-24.7M-10.7M-9.74M-80.1M-49.0M-82.9M-151.0M-90.9M
Shares outstanding8.42M5.77M2.08M1.92M1.57M1.18M757.3K311.2K242.3K9.55M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-25.3M-25.3M-19.1M-16.0M-19.3M-18.0M-23.0M-26.9M-44.6M-48.2M
Capital spending000-21.0K00-70.0K-5.00K-57.0K-87.0K
Free cash flow-25.3M-25.3M-19.1M-16.0M-19.3M-18.0M-23.1M-26.9M-44.6M-48.3M
Cash from investing004.40M-21.0K00242.0K7.00K-25.0K-83.0K
Cash from financing77.4M52.6M12.0M14.8M27.0M19.5M22.9M16.6M7.50M11.8M
Dividends paid-992.0K00
Share buybacks9.75M14.4M992.0K21.5M302.0K923.0K
Change in cash52.2M27.3M-2.68M-1.29M7.67M1.47M94.0K-10.2M-37.1M-36.5M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 8, 2026Big-stake noticeSEC
8-K · Current reportOct 6, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 29, 2026Meeting outcomeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
DEFA14A · Additional proxy materialJun 10, 2026Meeting noticeSEC
424B2 · ProspectusMay 13, 2026Offer documentSEC
8-K · Current reportMay 13, 2026Current reportSEC
S-8 · Registration statement for employee plansMay 13, 2026Offer documentSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 10, 2026Current reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026Current reportSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
8-K · Current reportFeb 2, 2026Material contractSEC
8-K · Current reportDec 19, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 9, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveNov 25, 2025Other filingsSEC
CORRESP · Letter to the SECNov 20, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
S-3 · Registration statementOct 3, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 25, 2025Big-stake noticeSEC
4 · Change in ownershipSep 25, 2025Insider tradeSEC
8-K · Current reportSep 10, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 8, 2025Big-stake noticeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 3, 2025Big-stake noticeSEC
8-K · Current reportSep 2, 2025Material contractSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 21, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Management or board changeSEC
8-K · Current reportMay 16, 2025Current reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
144 · Notice of proposed saleMay 1, 2025Other filingsSEC
144 · Notice of proposed saleApr 29, 2025Other filingsSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 24, 2025Insider tradeSEC
144 · Notice of proposed saleApr 24, 2025Other filingsSEC
3 · Initial statement of ownershipApr 11, 2025Insider tradeSEC
8-K · Current reportApr 11, 2025Management or board changeSEC
8-K · Current reportMar 31, 2025Current reportSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
8-K · Current reportMar 17, 2025Current reportSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
8-K · Current reportFeb 27, 2025Management or board changeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
8-K · Current reportOct 25, 2024Current reportSEC
S-8 · Registration statement for employee plansSep 23, 2024Offer documentSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportJul 26, 2024Current reportSEC
8-K · Current reportJul 2, 2024Material contractSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 13, 2024Insider tradeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveApr 30, 2024Other filingsSEC
424B2 · ProspectusApr 29, 2024Offer documentSEC
424B2 · ProspectusApr 29, 2024Offer documentSEC
CORRESP · Letter to the SECApr 25, 2024Other filingsSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
UPLOAD · Letter from the SECApr 16, 2024Other filingsSEC
S-3 · Registration statementApr 10, 2024Offer documentSEC
8-K · Current reportMar 26, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMar 22, 2024Big-stake noticeSEC
3 · Initial statement of ownershipMar 14, 2024Insider tradeSEC
8-K · Current reportMar 14, 2024Management or board changeSEC
10-K · Annual reportMar 13, 2024Annual reportSEC
8-K · Current reportMar 13, 2024ResultsSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 7, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 7, 2024Insider tradeSEC
DMar 7, 2024Other filingsSEC
SC 13D · Big-stake noticeMar 5, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeMar 5, 2024Big-stake noticeSEC
8-K · Current reportMar 5, 2024Current reportSEC
3 · Initial statement of ownershipFeb 29, 2024Insider tradeSEC
4 · Change in ownershipFeb 29, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 29, 2024Insider tradeSEC
8-K · Current reportFeb 28, 2024ResultsSEC
424B5 · ProspectusFeb 28, 2024Offer documentSEC
8-K · Current reportFeb 28, 2024Material contractSEC
8-K · Current reportDec 22, 2023Management or board changeSEC
8-K · Current reportDec 19, 2023Current reportSEC
8-K · Current reportDec 12, 2023Current reportSEC
8-K · Current reportNov 20, 2023Current reportSEC
8-K · Current reportNov 15, 2023Current reportSEC
8-K · Current reportNov 15, 2023Current reportSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023Current reportSEC
8-K · Current reportNov 1, 2023Acquisition or disposalSEC
DEF 14CSep 25, 2023Meeting noticeSEC
PRE 14CSep 15, 2023Meeting noticeSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportAug 11, 2023ResultsSEC
8-K · Current reportJul 20, 2023Current reportSEC
8-K · Current reportJun 26, 2023Current reportSEC
4/A · Change in ownership, amendedJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
8-K · Current reportJun 8, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
DEF 14A · Proxy statementApr 26, 2023Meeting noticeSEC
10-K · Annual reportMar 6, 2023Annual reportSEC
8-K · Current reportMar 6, 2023ResultsSEC
3 · Initial statement of ownershipMar 6, 2023Insider tradeSEC
8-K · Current reportFeb 1, 2023Current reportSEC
8-K · Current reportJan 6, 2023Current reportSEC
8-K · Current reportDec 23, 2022Current reportSEC
4 · Change in ownershipDec 13, 2022Insider tradeSEC
3 · Initial statement of ownershipDec 13, 2022Insider tradeSEC
8-K · Current reportDec 13, 2022Management or board changeSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
SC 13G · Big-stake noticeAug 23, 2022Big-stake noticeSEC
4 · Change in ownershipAug 18, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2022Insider tradeSEC
4 · Change in ownershipAug 17, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 17, 2022Insider tradeSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportAug 15, 2022ResultsSEC
8-K · Current reportAug 15, 2022Management or board changeSEC
3 · Initial statement of ownershipAug 8, 2022Insider tradeSEC
8-K · Current reportJul 27, 2022Management or board changeSEC
8-K · Current reportJul 25, 2022Material contractSEC
4 · Change in ownershipJul 15, 2022Insider tradeSEC
8-K · Current reportJul 15, 2022Management or board changeSEC
4 · Change in ownershipJul 6, 2022Insider tradeSEC
4 · Change in ownershipJul 6, 2022Insider tradeSEC
4 · Change in ownershipJul 6, 2022Insider tradeSEC
4 · Change in ownershipJul 6, 2022Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2022Insider tradeSEC
3 · Initial statement of ownershipJun 10, 2022Insider tradeSEC
SC 13D · Big-stake noticeJun 10, 2022Big-stake noticeSEC
3 · Initial statement of ownershipJun 10, 2022Insider tradeSEC
8-K · Current reportJun 3, 2022Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedJun 1, 2022Big-stake noticeSEC
8-K · Current reportJun 1, 2022Material contractSEC
8-K · Current reportMay 12, 2022ResultsSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
DEF 14A · Proxy statementMay 2, 2022Meeting noticeSEC
8-K · Current reportApr 15, 2022Management or board changeSEC
10-K/A · Annual report, amendedApr 5, 2022Annual reportSEC
8-K · Current reportApr 5, 2022Management or board changeSEC
10-K · Annual reportMar 29, 2022Annual reportSEC
8-K · Current reportMar 29, 2022ResultsSEC
4 · Change in ownershipMar 4, 2022Insider tradeSEC
8-K · Current reportMar 3, 2022Management or board changeSEC
8-K · Current reportFeb 18, 2022Current reportSEC

This page holds 200 of 603 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from vTv Therapeutics Inc.’s releases · as of Sep 2, 2025

Common shares
3,953,928
Fully diluted
3,953,928

Fully diluted

LineShares
Common shares3,953,928

Share count over time

CountShares
Nov 22, 20263,953,928

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Samsara Biocapital, LLC355K9.0%US$10.9MSep 30, 2026
Millennium342K8.7%US$10.6MSep 30, 2026
Fidelity260K6.6%US$8.03MSep 30, 2026
Siren, L.L.C.163K4.1%US$5.03MSep 30, 2026
Baker Bros. Advisors LP148K3.8%US$4.57MSep 30, 2026
Vanguard94,2062.4%US$2.91MSep 30, 2026
Trails Edge Capital Partners, LP76,9891.9%US$2.37MSep 30, 2026
Aisling Capital Management LP58,7751.5%US$1.81MSep 30, 2026
Two Sigma47,6541.2%US$1.47MSep 30, 2026
Geode Capital24,3500.62%US$752KSep 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
Hrt Financial LP24,1670.61%US$745KSep 30, 2026
Marshall Wace, LLP23,8830.60%US$737KSep 30, 2026
Renaissance Technologies21,3060.54%US$657KSep 30, 2026
Morgan Stanley17,4760.44%US$539KSep 30, 2026
Verdad Advisers, LP15,9700.40%US$493KSep 30, 2026
BlackRock14,3950.36%US$444KSep 30, 2026
State Street13,0660.33%US$403KSep 30, 2026
Prudential Financial Inc12,2180.31%US$377KSep 30, 2026
UBS11,3190.29%US$349KSep 30, 2026
Acadian Asset Management LLC7,2760.18%US$223KSep 30, 2026
China Universal Asset Management Co., Ltd.5,3600.14%US$161KSep 30, 2026
Barclays4,0980.10%US$126KSep 30, 2026
Osaic Holdings, Inc.1,0200.03%US$30,615Sep 30, 2026
Tower Research Capital LLC (TRC)5180.01%US$15,975Sep 30, 2026
Farther Finance Advisors, LLC283<0.01%US$8,728Sep 30, 2026
Strengthening Families & Communities, LLC173<0.01%US$5,335Sep 30, 2026
Wells Fargo100<0.01%US$3,084Sep 30, 2026
State of Wyoming96<0.01%US$2,961Sep 30, 2026
Activest Wealth Management50<0.01%US$1,542Sep 30, 2026
CoreCap Advisors, LLC45<0.01%US$1,388Sep 30, 2026
Parallel Advisors, LLC38<0.01%US$1,172Sep 30, 2026
BNP Paribas9<0.01%US$278Sep 30, 2026
Caitong International Asset Management Co., Ltd6<0.01%US$185Sep 30, 2026
RBC3<0.01%Sep 30, 2026
SBI Securities Co., Ltd.2<0.01%US$62Sep 30, 2026
Strategic Wealth Partners, Ltd.1<0.01%US$31Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Select Biotechnology Portfolio260K6.6%US$8.68MMay 31, 2026
Vanguard Total Stock Market Index Fund60,7631.5%US$2.29MJun 30, 2026
Vanguard Extended Market Index Fund31,4020.79%US$1.18MJun 30, 2026
Fidelity Extended Market Index Fund14,7320.37%US$491KMay 31, 2026
iShares Micro-Cap ETF7,2340.18%US$272KJun 30, 2026
Fidelity Total Market Index Fund4,7790.12%US$159KMay 31, 2026
Fidelity Series Total Market Index Fund4,1930.11%US$140KMay 31, 2026
Fidelity Nasdaq Composite Index Fund2,5240.06%US$84,175May 31, 2026
Vanguard Institutional Total Stock Market Index Fund1,5230.04%US$57,341Jun 30, 2026
Vanguard Balanced Index Fund7750.02%US$29,179Jun 30, 2026
All 14 holders
HolderSharesOf the companyValueAs of
1290 VT Micro Cap Portfolio4860.01%US$18,298Jun 30, 2026
Victory Extended Market Index Fund236<0.01%US$7,635Jul 31, 2026
Total Stock Market Index Trust88<0.01%US$3,313Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND11<0.01%US$356Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Srinivas Akkaraju9.90%413KNov 12, 2026Schedule 13D
Trails Edge Capital Partners, LP9.90%341KAug 29, 2025Schedule 13G
Raymond Debbane9.40%393KSep 30, 2025Schedule 13G
Millennium Management LLC8.70%342KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Felix Baker
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past)
Director · Since at least Feb 27, 2024
Julian Baker
Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past)
Director · Since at least Feb 27, 2024
Paul Meister
Other companies: Versigent PLC (Director · Since at least Apr 1, 2026); Amneal Pharmaceuticals, Inc. (Chairman of the Board · Since at least Aug 2, 2019); Aptiv PLC (Lead Independent Director · Since at least Jul 25, 2019); Quanterix Corporation (Director · Since at least Dec 6, 2017); Oaktree Acquisition Corp. III Life Sciences (Director · Oct 23, 2024 – Oct 23, 2024 · Past); Telesis Bio, Inc. (Director · Jun 5, 2023 – Jun 6, 2023 · Past); Oaktree Acquisition II Corp (Director · Sep 16, 2020 – Sep 16, 2020 · Past); Hims & Hers Health, Inc. (Director · Jul 17, 2019 – Jul 17, 2019 · Past); Revlon Inc (Director · Jun 9, 2016 – Jun 9, 2016 · Past); Light & Wonder, Inc. (Director · Mar 20, 2012 – Jun 10, 2020 · Past); M & F Worldwide Corp (Director · Apr 30, 2007 – Dec 21, 2011 · Past); Thermo Fisher Scientific Inc (Director · Nov 9, 2006 – Jan 5, 2007 · Past); LKQ Corporation (Director · Mar 31, 2006 – May 8, 2017 · Past); Fisher Scientific International Inc (Vice Chairman, Director · Jan 13, 2006 – Nov 9, 2006 · Past)
Director · Jul 30, 2015 – Jul 30, 2015 · Past
Daniel K. Spiegelman
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Kyverna Therapeutics, Inc. (Director · Since at least Feb 7, 2024); Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020); Jiya Acquisition Corp (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Myriad Genetics, Inc. (Director · May 27, 2020 – Jun 6, 2024 · Past); Relypsa Inc (Director · Jun 19, 2014 – Sep 1, 2016 · Past); BioMarin Pharmaceutical Inc. (EVP, Chief Financial Officer · May 29, 2012 – Apr 30, 2019 · Past); Anthera Pharmaceuticals Inc (Director · Feb 23, 2010 – Jun 13, 2014 · Past); Omeros Corporation (Director · Dec 8, 2009 – Jun 1, 2012 · Past); Cascadian Therapeutics Inc (Director · Jun 4, 2008 – Mar 9, 2018 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Bio Green Med Solution, Inc. (Director · Jun 14, 2006 – May 23, 2012 · Past); CV Therapeutics Inc (SVP, CFO · Jan 3, 2006 – Apr 16, 2009 · Past)
Director · Since at least Jun 11, 2024
Srinivas Akkaraju
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Alumis Inc. (Founder and Managing Member, Samsara BioCapital · Since at least Jun 27, 2024); Mineralys Therapeutics, Inc. (Board Member · Since at least Feb 9, 2023); Scholar Rock Holding Corporation (Director · Since at least Jul 26, 2022); Jiya Acquisition Corp (Director · Sep 23, 2022 – Sep 23, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 1, 2022 – Sep 16, 2024 · Past); Aduro Biotech Inc (Director · May 26, 2022 – Aug 11, 2023 · Past); Intercept Pharmaceuticals Inc (Director · May 25, 2022 – Nov 8, 2023 · Past)
Director · Since at least Feb 23, 2024
Paul Sekhri
Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Veeva Systems Inc. (Director · Since at least Jun 22, 2016); Axcella Health Inc (Director · May 19, 2022 – May 19, 2022 · Past); Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past); BiomX Inc. (Director · Oct 2, 2020 – Jul 28, 2021 · Past); Enumeral Biomedical Holdings Inc (Director · Dec 9, 2016 – Dec 9, 2016 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Jan 2, 2020 · Past)
Chairman of the Board, President and Chief Executive Officer · Since at least Aug 1, 2022
Anne Phillips
Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Aug 1, 2024); Trevena, Inc. (Member of Nominating and Corporate Governance Committee · Since at least Dec 16, 2014); Vaccitech plc (Director · Apr 29, 2021 – May 11, 2023 · Past); AMAG Pharmaceuticals Inc (Director · Apr 10, 2019 – Nov 16, 2020 · Past)
Director · Since at least Mar 13, 2024
Craig Parker
Other companies: Surrozen, Inc. (Chief Executive Officer · Since at least Aug 11, 2021); Geron Corporation (EVP, Corp Dev & Sci Affairs · Dec 3, 2012 – Feb 10, 2014 · Past); Human Genome Sciences Inc (Sr VP Strategy and Corporate D · Aug 8, 2011 – Jul 30, 2012 · Past)
Director · Jul 30, 2015 – Apr 30, 2018 · Past
Hersh Kozlov
Other companies: BTC Development Corp. (Director · Since at least Sep 29, 2025); The Bancorp, Inc. (Director · Since at least Jan 27, 2014); Resource America Inc (Director · Aug 9, 2007 – Sep 8, 2016 · Past)
Director · Sep 11, 2019 – Jun 19, 2023 · Past
Noel J. Spiegel
Other companies: American Eagle Outfitters, Inc. (Lead Independent Director · Since at least Jun 21, 2011); Radian Group Inc. (Director · Since at least Feb 9, 2011); XWELL, Inc. (Director · May 7, 2013 – Jan 22, 2015 · Past)
Director · Jul 30, 2015 – May 3, 2021 · Past
All 27 people
PersonSeat
Paul G Savas
Other companies: Revlon Inc (Director · Jun 9, 2016 – Nov 11, 2016 · Past); SIGA Technologies Inc. (Director · May 23, 2012 – Jun 16, 2020 · Past); M & F Worldwide Corp (Executive Vice President & CFO · Dec 21, 2011 – Dec 21, 2011 · Past)
Director · Jul 30, 2015 – Sep 6, 2018 · Past
Rudy Howard
Other companies: Aravive Inc (Chief Financial Officer · Jun 3, 2022 – Feb 1, 2023 · Past); Amber Road Inc (Director · Mar 20, 2014 – Jul 2, 2019 · Past); SciQuest Inc (Chief Financial Officer · Sep 20, 2010 – May 27, 2015 · Past)
CFO & Secretary · Jul 30, 2015 – Dec 7, 2020 · Past
Edward P Taibi
Other companies: Archaea Energy Inc (GC, EVP Strat Init & Gov Aff · Mar 21, 2022 – Dec 28, 2022 · Past); SIGA Technologies Inc. (Director · Aug 6, 2020 – Aug 6, 2020 · Past)
Director · Aug 31, 2020 – Aug 31, 2020 · Past
Raymond Cheong
Other companies: Madrigal Pharmaceuticals, Inc. (Director · Jun 15, 2023 – Jun 15, 2023 · Past); Talis Biomedical Corp (Director · Feb 11, 2021 – Mar 10, 2023 · Past)
Lead Independent Director · Since at least Feb 27, 2024
Deepa Prasad
Other companies: Design Therapeutics, Inc. (Director · Since at least Jun 15, 2021)
President and CEO, Director · Oct 19, 2021 – Oct 19, 2021 · Past
John A Fry
Other companies: Community Health Systems, Inc. (Director · Since at least Jan 3, 2006)
Director · Mar 16, 2016 – Jun 19, 2023 · Past
Keith R. Harris
Other companies: MeiraGTx Holdings plc (Chairman of the Board · Since at least Jun 8, 2018)
Director · Jul 11, 2022 – Jun 19, 2023 · Past
Barry K BrownChief Accounting Officer · Apr 11, 2025 – Apr 11, 2025 · Past
Chandresh HarjivanDirector · Jun 1, 2022 – Jun 19, 2023 · Past
Fahed Al MarzooqiDirector · Since at least May 31, 2022
Howard L WeinerDirector · Jul 31, 2017 – Jun 19, 2023 · Past
Jonathan IsaacsohnDirector · Aug 9, 2022 – Aug 17, 2022 · Past
Martin LafontaineChief Commercial Officer · Mar 20, 2025 – Nov 5, 2026 · Past
Michael TungEVP & CFO · Since at least May 19, 2025
Rich NelsonExecutive Vice President, Corporate Development · Since at least Nov 16, 2020
Stephen L HolcombePresident & CEO · Jul 30, 2015 – Dec 7, 2020 · Past
Steven L TuchChief Financial Officer · Dec 8, 2022 – Feb 27, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about vTv Therapeutics Inc.